Table 2 AEF of viable tumor before and after DEB-TACE
Whole patients (n = 158) | Patients excluding CR response (n = 144) | |||||
|---|---|---|---|---|---|---|
AEFpre (%) | p* | AEFpre (%) | AEFpost (%) | Decrease ratio | p† | |
Whole patients | 52.6 ± 14.2 | – | 52.5 ± 14.2 | 46.9 ± 16.5 | 0.12 (− 0.02, 0.26) | < 0.001 |
Child-Pugh class | ||||||
A | 51.1 ± 13.9 | 0.012 | 51.1 ± 14.1 | 46.3 ± 15.8 | 0.09 (− 0.05, 0.26) | < 0.001 |
B | 57.9 ± 14.1 | 58.0 ± 13.4 | 49.2 ± 19.1 | 0.14 (0.04, 0.30) | 0.002 | |
AFP (ng/ml) | ||||||
≤ 400 | 51.4 ± 14.9 | 0.279 | 51.4 ± 15.1 | 44.1 ± 16.9 | 0.14 (0.04, 0.26) | < 0.001 |
> 400 | 54.2 ± 13.1 | 54.0 ± 13.1 | 50.3 ± 15.6 | 0.06 (− 0.12, 0.27) | 0.019 | |
Lesion margin | ||||||
Smooth | 53.8 ± 12.9 | 0.219 | 53.9 ± 12.9 | 45.1 ± 16.5 | 0.17 (0.04, 0.29) | < 0.001 |
Non-smooth | 51.0 ± 15.6 | 51.0 ± 15.5 | 49.0 ± 16.5 | 0.06 (− 0.13, 0.22) | 0.143 | |
Macrovascular invasion invasion | ||||||
Absent | 52.9 ± 14.3 | 0.758 | 52.8 ± 14.3 | 43.6 ± 16.8 | 0.17 (0.05, 0.29) | < 0.001 |
Present | 52.2 ± 14.1 | 52.2 ± 14.2 | 51.8 ± 14.9 | 0.05 (−0.20, 0.17) | 0.516 | |
Treatment response | ||||||
CR | 53.3 ± 14.6 | 0.988 | – | – | – | – |
PR | 52.7 ± 13.3 | 52.7 ± 13.3 | 38.9 ± 13.8 | 0.26 (0.18, 0.37) | < 0.001 | |
SD | 52.1 ± 15.0 | 52.1 ± 15.0 | 49.3 ± 16.1 | 0.05 (−0.03, 0.11) | 0.029 | |
PD | 53.0 ± 14.6 | 53.0 ± 14.6 | 55.5 ± 16.0 | 0.07 (−0.31, 0.17) | 0.604 | |